BRCA2 and ovarian cancer: In addition, Qianying et al. shed light on a group of genes involved in cisplatin resistance in ovarian cancer cells, identifying ZNF587B as a novel predictive marker [88], whereas Stover et al. performed a near genome CRISPR/Cas9 screen in BRCA2 mutant HGSOC cell lines and identified BCL2L1 as a gene that mediates resistance to platinum-based chemotherapy [89].